Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical... see more

CSE:BIOV - Post Discussion

BioVaxys Technology Corp. > BIOV I REPOST JULY 13TH POST WITH CLARITY~thanks doxiedollar
View:
Post by moneywagon on Jul 18, 2022 7:58am

BIOV I REPOST JULY 13TH POST WITH CLARITY~thanks doxiedollar

 


BioVaxys Technology Corp.
246 Tweets
Follow
 
 
 
 
 
 
 
 
Opens profile photo
 
Follow
BioVaxys Technology Corp.
@biovaxys
 
BioVaxys (CSE:BIOV FSE:5LB OTCQB:BVAXF) is an immunotherapeutics company developing viral & oncology vaccine platforms, and T-cell immuno-diagnostics ($biov.c)
Commercial & IndustrialVancouver, Canadabiovaxys.com
 

BioVaxys Technology Corp.’s Tweets

 
 
 
 
 
 
 
 
BioVaxys Technology Corp.
 
@biovaxys
Successful vaccine dose (non-GMP) production with >96% binding of cancer cells to haptens following 1st ovarian tumor surgical debulking. Tests on 2nd ovarian tumor sample ongoing, 3rd tumor excision upcoming from Hospice Civils de Lyon.
Quote Tweet
 
 
BioVaxys Technology Corp.
 
@biovaxys
·
Excellent news! EU clinical collaborator Hospice Civils de Lyon surgically excised a second ovarian tumor to be used for vaccine process validation. $BIOV also received Institutional Review Board approval from #Deaconess in the US for surgically excised tumor samples @CHUdeLyon
Be the first to comment on this post
BioVaxys Technology Corp.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities